HDAC-IN-31 是一种有效、选择性且具有口服活性的 HDAC 抑制剂,对 HDAC1、HDAC2、HDAC3 和 HDAC8 的 IC50 值分别为 84.90、168.0、442.7 和 >10000 nM,可诱导细胞凋亡(apoptosis)和 G2/M 期细胞周期停滞,显示出良好的抗肿瘤功效,并具有研究弥漫性大B细胞淋巴瘤的潜力。
产品编号: MS-O69640 CAS No.: 1916505-13-9 分子式: C25H24N4O2 分子量: 412.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

HDAC-IN-31 是一种有效、选择性且具有口服活性的 HDAC 抑制剂,对 HDAC1、HDAC2、HDAC3 和 HDAC8 的 IC50 值分别为 84.90、168.0、442.7 和 >10000 nM,可诱导细胞凋亡(apoptosis)和 G2/M 期细胞周期停滞,显示出良好的抗肿瘤功效,并具有研究弥漫性大B细胞淋巴瘤的潜力。

生物实验数据

生物活性 HDAC-IN-31 is a potent, selective, and orally active HDAC inhibitor with IC50 values of 84.90, 168.0, 442.7, and >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC8, respectively, which induces apoptosis and G2/M cell cycle arrest, exhibits favorable antitumor efficacy, and holds potential for the investigation of diffuse large B-cell lymphoma.
IC50 & Target HDAC8:>10000 nM, HDAC3:442.7 nM, HDAC2:168.0 nM, HDAC1:84.90 nM
体外研究
(In Vitro)

HDAC-IN-31 (compound 24g) (2 µM) shows growth-inhibitory activities with the inhibition rate of 2.32%, 44.01%, 48.53%, 64.94% for TMD-8, HCT 116, A549, MDA-MB-231 cells.
HDAC-IN-31 (1 µM) shows selectivity with the IC50s of 84.9, 168.0, 442.7, >10000 nM for HDAC 1, HDAC 2, HDAC 3, HDAC 8, and 81.20%, 84.43%, 88.07%, 92.34%, 96.88%, 91.98% enzyme activity for HDAC4, HDAC 5,HDAC 7, HDAC9, HDAC 6, HDAC 11, respectively.
HDAC-IN-31 (2.5, 5, 7.5, 10 µM; 24 h) increases the expression of HDAC1, Ace-H3, Ace-H4, Cleaved PARP, Cleaved Caspase-3 in a dose-dependent manner.
HDAC-IN-31 (0-4 µM; 24 h)induce apoptosis and cell cycle arrests in G2/M phase in a dose-dependent manner.

Cell Proliferation Assay

Cell Line: MDA-MB-231, A549, NCI-H460, HCT-116,SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells
Concentration: 0-20 µM
Incubation Time: 72 h
Result: Showed a broad spectrum of antitumor activity with the IC50s of 2.29, 2.85, 1.58, 1.16, 3.17, 2.41, 8.02, 2.62, 1.14, 0.60, 0.31, 0.39, 0.48, 0.51, 0.33, 0.38, 0.80, 0.47 µM for MDA-MB-231, A549, NCI-H460, HCT-116, SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells, respectively.

Western Blot Analysis

Cell Line: TMD-8 cells
Concentration: 2.5, 5, 7.5, 10 µM
Incubation Time: 24 h
Result: Promoted the HDAC1, HDAC2, HDAC3 substrate Ace-H3 and Ace-H4 acetylation with a dose-dependent manner.

Apoptosis Analysis

Cell Line: TMD-8 cells
Concentration: 0.5, 1, 2, 4 µM
Incubation Time: 24 h
Result: Induced cell apoptosis at a concentration-dependent manner.

Cell Cycle Analysis

Cell Line: TMD-8 cells
Concentration: 250, 500, 1000 nM
Incubation Time: 24 h
Result: Arrested the cell cycle at G2/M phase in a dose-dependent manner.
体内研究
(In Vivo)

HDAC-IN-31 (2 mg/kg for i.v.; 10, 100 mg/kg for p.o.) shows good bioavailability with a significant dose dependent manner.
HDAC-IN-31 (50, 100 mg/kg; p.o, daily for 21 consecutive days) shows good antitumor efficacy in a TMD-8 xenograft model without obvious toxicity.
Pharmacokinetic Parameters of HDAC-IN-31 in mice.

Parameters Unit 24 g (25 mg/kg)
Cmax ng·h·mL-1 3100±231
T1/2(po) h 4.4±0.3
AUC0-inf(iv) ng·h·mL-1 1040±142
AUC0-inf(po) ng·h·mL-1 5180±252
MRTPO h 2.6±0.4
F % 39.9±2.1
ICR mouse; 2 mg/kg for i.v.; 25 mg/kg for p.o..
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models.
Parameters Unit po (25 mg/kg) po (50 mg/kg) po (100 mg/kg)
Cmax ng·h·mL-1 1700±317 14700±1024 10700±1001
AUC0-t ng·h·mL-1 1220±242 9710±314 9740±230
AUC0-inf ng·h·mL-1 1230±165 9730±341 9770±332
MRT0-t h 0.750±0.043 0.812±0.023 1.43±0.56
MRT0-inf h 0.805±0.086 0.821±0.041 1.51±0.32
Mouse; 25, 50, 100 mg/kg for p.o..
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models.
PK parameters Unit iv (2 mg/kg) po (10 mg/kg) po (100 mg/kg)
Cmax ng·h·mL-1 3960±413 58300±1352
T1/2 h 0.427±0.016 1.31±0.27 1.63±0.52
AUC0-inf ng·h·mL-1 1250±132 2670±286 57200±1047
MRT h 0.402±0.032 0.919±0.052 0.897±0.041
CL mL·kg·min-1 27.2±1.2
F % 45.6±1.2 91.8±2.3
ICR mice; 2 mg/kg for i.v.; 10, 100 mg/kg for p.o..
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models.
PK parameters Unit Monkey Dog
iv (1 mg/kg) po (10 mg/kg) iv (1 mg/kg) po (10 mg/kg)
Cmax ng·h·mL-1 8520±301 4740±243
T1/2 h 4.31±0.56 9.14±0.32 1.65±0.41 1.51±0.33
AUC0-inf ng·h·mL-1 15700±1842 53200±1241 2550±365 15100±2004
MRT h 3.41±0.12 8.28±0.32 2.26±0.41 2.71±0.32
CL mL·kg·min-1 1.35±0.21 6.72±0.35
Vdss L·kg-1 0.34±0.22 0.55±0.04
F % 27.6±2.1 58.9±1.2
Dogs and monkeys; 1 mg/kg for i.v., 10 mg/kg for p.o. for monkey; 1 mg/kg for i.v., 10 mg/kg for p.o. for dog.

Animal Model: ICR mice
Dosage: 2 mg/kg for i.v.; 25 mg/kg for p.o.(DMSO/PEG200/saline = 20:20:60, v/v/v)
Administration: I.v. or p.o.
Result: Showed high oral bioavailability (F=40%).
Animal Model: Mouse
Dosage: 25, 50, 100 mg/kg
Administration: P.o.
Result: Did not exhibit a significant dose dependent for oral administration.
Animal Model: ICR mice
Dosage: 2, 10, 100 mg/kg (into the form of hydrochloride)
Administration: 2 mg/kg for i.v.; 10, 100 mg/kg for p.o.
Result: Showed good bioavailability with a significant dose dependent.
Animal Model: Dogs and monkeys
Dosage: 1, 10 mg/kg
Administration: 1 mg/kg for i.v.; 10 mg/kg for p.o.
Result: Showed good pharmacokinetic characteristics for different species.
Animal Model: 5-6 weeks, female CB.17 SCID mice (TMD-8 tumor xenografts)
Dosage: 50, 100 mg/kg
Administration: P.o, daily for 21 consecutive days
Result: Inhibited the tumor growth with the inhibition rate of 77% and had no significant effect on the internal organs of mice at 100 mg/kg/d.

化学信息

分子量 412.48
分子式 C25H24N4O2
CAS No. 1916505-13-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础